Pharmaceutical Industry Articles & Reports - Page 3

Analyze Gilead's $5 billion acquisition of Tubulis, examining antibody-drug conjugate (ADC) oncology strategy, market trends, and new clinical platforms.

Review China NMPA drug approval pathways, regulatory strategy, and ICH harmonization. Examine priority, breakthrough, and conditional approval processes.

A detailed analysis of the Takeda-Iambic AI drug discovery partnership. Examine the $1.7B deal terms, NeuralPLexer technology, and AI pharma industry trends.

Comprehensive analysis of Roche Navify Clinical Hub, detailing its platform architecture, AI features, oncology tumor board workflows, and trial matching.

Read an analysis of Amazon Bio Discovery, an AWS agentic AI platform integrating biological foundation models and wet-lab workflows for drug development.

Compare Microsoft 365 and Google Workspace for pharmaceutical GxP compliance. Learn how each cloud platform meets FDA 21 CFR Part 11 and data integrity rules.

Analyze Insilico Medicine's Pharma.AI platform for AI drug discovery. Learn how PandaOmics, Chemistry42, and MMAI Gym integrate for target and molecule design.

Review the core requirements for 21 CFR Part 11 compliance in pharma. This guide explains FDA electronic records, signatures, ALCOA+, and system validation.

Guide to pharma AI procurement with comprehensive RFP templates and weighted vendor scorecards. Review FDA compliance, data privacy, and GxP criteria.

Understand FDA Predetermined Change Control Plans (PCCPs) for AI/ML Software as a Medical Device. Review Section 515C, FDA guidance, and implementation.

Examine how fine-tuning foundation models and LLMs improves pharmaceutical R&D and drug discovery. Review Insilico's MMAI Gym methodology and AI benchmarks.

This guide details how bioanalytical LIMS software ensures method validation and regulatory compliance with FDA 21 CFR Part 11, ICH M10, and GLP standards.

An in-depth analysis of the Amazon Bio Discovery platform. Learn how AWS uses agentic AI, biological foundation models, and integrated wet labs for drug R&D.

Examine the Novo Nordisk and OpenAI partnership to understand enterprise AI strategy in pharma. Explore generative AI applications in drug R&D and manufacturing

Analyze the FDA's 2025 AI-driven enforcement of prescription drug advertising. This report details DTC compliance changes, warning letters, and pharma impacts.

Explore how artificial intelligence is applied in pharmaceutical QC labs to automate OOS investigations, real-time batch release, and stability data analysis.

Guide to structuring a board-ready business case for enterprise AI in pharma. Review investment planning, ROI metrics, implementation strategies, and use cases.

Examine the FDA's enforcement of ClinicalTrials.gov reporting mandates, historic compliance gaps among trial sponsors, and AI solutions for data disclosure.

Explore how AI target discovery and graph-based machine learning platforms like bfLEAP address R&D challenges in central nervous system drug development.

Examine clinical evidence generation for AI diagnostic SaMD. This report covers real-world performance studies, FDA guidelines, and post-market surveillance.

Review the $12B wave of Q1 2026 oncology AI deals and pharma M&A. This analysis explains how patent cliffs, CAR-T, and AI drug discovery drive acquisitions.

Guide to designing an AI training program for pharmaceutical teams. Review role-based curriculum development, learning tools, and ROI measurement frameworks.

Analyze how Roche utilizes its NVIDIA AI factory, featuring 3,500 GPUs and Omniverse digital twins, to scale GLP-1 drug manufacturing and optimize pharma R&D.

Examine the 2026 AI digital health landscape. Learn how Big Tech, pharmaceutical companies, and startups compete and collaborate in AI-powered healthcare.